Robert Huisden

379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study

Peter Schmid, Piotr J. Wysocki, Y.H. Park et al. · Annals of Oncology · 2023 · 46 citations · Full text

Medicine, Oncology, Pharmacology +14

166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study

Patrick Schmid, K.H. Jung, Piotr J. Wysocki et al. · Annals of Oncology · 2022 · 43 citations

Medicine, Oncology, Pharmacology +16

Abstract PD11-08: PD11-08 Trastuzumab deruxtecan (T-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic hormone receptor-negative (HR−), HER2-low breast cancer: updated results from BEGONIA, a phase 1b/2 study

Peter Schmid, Piotr J. Wysocki, Yeon H. Park et al. · Cancer Research · 2023 · 30 citations

Medicine, Oncology, Pharmacology +17

Abstract PD11-09: PD11-09 Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study

Peter Schmid, Piotr J. Wysocki, Yeon H. Park et al. · Cancer Research · 2023 · 12 citations · Full text

Medicine, Oncology, Pharmacology +17